DBV Technologies appoints former US FDA chief counsel to board
This article was originally published in Clinica
Executive Summary
DBV Technologies (Paris, France), a developer of non-invasive epicutaenous diagnostics and immunotherapies for allergies, has appointed Peter Barton Hutt as a non-executive director. Mr Hutt is currently a senior counsel at Covington & Burling law firm (Washington, DC) where he specialises in food and drug law – which he also teaches at Harvard Law School. A former chief counsel for the US FDA, Mr Hutt has first-hand experience of US FDA legislation. He is a member of the US Institute of Medicine.